Drug FDA Class II Ongoing cGMP deviation
Atomoxetine Capsules, USP, 18 mg, 30 capsule bottles, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ, USA, Product of India, NDC 68462-266-30.
Glenmark Pharmaceuticals Inc., USA Published Feb 26, 2025
Risk level
Class IIMay cause a temporary or reversible health problem; slight chance of serious harm.
Severity score 60/100
What should you do?
- Check whether you have this product, using the lot codes, UPCs, and dates listed below.
- Do not eat, serve, or sell the affected product.
- Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
- Contact Glenmark Pharmaceuticals Inc., USA or your place of purchase with questions, and see the source record below for full details.
Reason for recall
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Hazards
N-Nitroso Atomoxetine · primary
Affected products (1)
Atomoxetine Capsules, USP, 18 mg, 30 capsule bottles, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ, USA, Product of India, NDC 68462-266-30.
ATOMOXETINE · 56,208 bottles
NDC: 68462-265, 68462-266, 68462-267, 68462-268, 68462-269, 68462-270, 68462-271, 68462-265-30, 68462-265-23, 68462-266-30, 68462-266-23, 68462-267-30, 68462-267-23, 68462-268-30, 68462-268-23, 68462-269-30, 68462-269-23, 68462-270-30, 68462-270-23, 68462-271-30, 68462-271-51
Lot codes: Numbers
Code info: Lot Numbers: 19233756, Exp.: 8/2025; 19235111, Exp.: 11/2025; 19242167, Exp.: 5/2026; 19242180, Exp.: 5/2026.
Affected areas
Nationwide
Timeline
- InitiatedJan 29, 2025
- PublishedFeb 26, 2025
- Recall number
- D-0232-2025
- Agency
- U.S. Food and Drug Administration
- Country
- US
FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.